Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Repligen (NASDAQ: RGEN) announced that Dr. Martin D. Madaus was elected Chair of the Board effective March 13, 2026, as Executive Chair Tony Hunt retires from the Board on that date and will remain as an advisor through March 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen (NASDAQ: RGEN) announced that Dr. Martin D. Madaus was elected Chair of the Board effective March 13, 2026, as Executive Chair Tony Hunt retires from the Board on that date and will remain as an advisor through March 2027. Dr. Madaus has served as a Repligen director since February 2023 and brings 36 years of industry experience, including five years as Chairman, President and CEO of Millipore and involvement in its 2010 acquisition by Merck KGaA. Dr. Madaus also serves on the boards of Azenta and Hologic and holds a D.V.M. and Ph.D. from universities in Germany.
Positive
- New Chair effective March 13, 2026
- Tony Hunt advisory role through March 2027
- Dr. Madaus 36 years industry experience
Negative
- Executive Chair role vacated on March 13, 2026
Details
News Market Reaction – RGEN
On Jan 6, the day this news came out, RGEN closed 1.66% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Effective date
- March 13, 2026
- Martin D. Madaus becomes Chair of the Board
- Advisor term end
- March 2027
- Tony Hunt to remain advisor to Repligen
- Industry experience
- 36 years
- Dr. Madaus’ total industry experience
- Millipore leadership tenure
- 5 years
- Time as Chairman, President and CEO of Millipore Corporation
- Current price
- $169.44
- Pre-news trading level for RGEN
- 52-week high
- $182.52
- RGEN trading below its 52-week high
- 52-week low
- $102.965
- RGEN significantly above its 52-week low
- Market cap
- $9,251,384,598
- Equity value prior to the leadership change news
Historical Context
-
J.P. Morgan 2026 Healthcare Conference presentation announcement.
-
Launch of next-generation chromatography resins for new modalities.
-
Participation in Evercore healthcare conference with webcast access.
-
Schedule of multiple November investor conferences with management.
-
Q3 2025 beat, raised full-year guidance and strong growth metrics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq financial
board of directors regulatory
bioprocessing technical
biopharma technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027.
“On behalf of Repligen, I want to thank Tony for over a decade of service to the Company, during which he expanded our unique and diversified portfolio of innovative products,” said Olivier Loeillot, Repligen President and CEO. “He left a strong foundation for us to build upon, and with Martin assuming the role of Chair of the Board, we are well-positioned for success. Martin’s deep expertise and strong leadership in bioprocessing and biopharma makes him exceptionally qualified to lead our Board.”
Dr. Martin D. Madaus added, “On behalf of the Board of Directors, our shareholders, employees, and other stakeholders, I want to commend Tony on his impressive tenure at Repligen. I am honored to be elected as Chair of the Repligen Board and look forward to guiding Repligen towards new heights.”
Tony Hunt said, “After more than a decade of leadership, I leave this Company immensely proud of the business we have created together. One that is rooted in clear strategy, disciplined execution and outstanding people. It has been a privilege and an honor to work alongside such a committed team, and I leave knowing the Company is in very capable hands. I am confident that Olivier and Martin will build on the success we have enjoyed and lead Repligen to a new phase of growth.”
Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta, Inc. and Hologic, Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
________________________
1 Repligen June 14, 2024 8-K
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.